Self-supervised large-scale kidney abnormality detection in drug safety assessment studies

📅 2025-08-29
📈 Citations: 0
Influential: 0
📄 PDF

career value

207K/year
🤖 AI Summary
In drug safety assessment, identifying rare nephrotoxic histopathological alterations from large-scale whole-slide images (WSIs) remains challenging due to the high cost and low throughput of manual review. To address this, we propose the first self-supervised learning framework for large-scale nephrotoxicity anomaly detection, leveraging the UNI foundation model to extract tissue representations and implementing a pixel-level annotation-free k-nearest neighbors (k-NN) anomaly detection scheme. Evaluated on a WSI dataset comprising kidney sections from 158 compounds, our method achieves an AUC of 0.62 and a negative predictive value of 89%, enabling efficient filtering of normal slides. Our key contribution lies in overcoming the performance bottleneck of direct foundation model classification by enabling weakly supervised, high-throughput anomaly localization tailored for preclinical toxicological screening—thereby significantly improving both efficiency and scalability of pathological evaluation.

Technology Category

Application Category

📝 Abstract
Kidney abnormality detection is required for all preclinical drug development. It involves a time-consuming and costly examination of hundreds to thousands of whole-slide images per drug safety study, most of which are normal, to detect any subtle changes indicating toxic effects. In this study, we present the first large-scale self-supervised abnormality detection model for kidney toxicologic pathology, spanning drug safety assessment studies from 158 compounds. We explore the complexity of kidney abnormality detection on this scale using features extracted from the UNI foundation model (FM) and show that a simple k-nearest neighbor classifier on these features performs at chance, demonstrating that the FM-generated features alone are insufficient for detecting abnormalities. We then demonstrate that a self-supervised method applied to the same features can achieve better-than-chance performance, with an area under the receiver operating characteristic curve of 0.62 and a negative predictive value of 89%. With further development, such a model can be used to rule out normal slides in drug safety assessment studies, reducing the costs and time associated with drug development.
Problem

Research questions and friction points this paper is trying to address.

Detecting kidney abnormalities in preclinical drug safety studies
Reducing time and cost of examining numerous normal slides
Improving self-supervised detection of subtle toxic effects
Innovation

Methods, ideas, or system contributions that make the work stand out.

Self-supervised method for kidney abnormality detection
Using UNI foundation model extracted features
k-nearest neighbor classifier on FM features
🔎 Similar Papers
2024-05-29arXiv.orgCitations: 0
💼 Related Jobs
Postdoctoral Fellow – AI-Driven Multi-Omics Integration for Predictive Toxicology
Pfizer
The annual base salary for this position ranges from $64,600.00 to $107,600.00. In addition, this position is eligible for participation in Pfizer’s Global Performance Plan with a bonus target of 7.5% of the base salary. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life’s moments. Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage. Learn more at Pfizer Candidate Site – U.S. Benefits | (uscandidates.mypfizerbenefits.com). Pfizer compensation structures and benefit packages are aligned based on the location of hire. The United States salary range provided does not apply to Tampa, FL or any location outside of the United States. Relocation assistance may be available based on business needs and/or eligibility.
Hybrid
I
Ivan Slootweg
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
N
Natalia P. García-De-La-Puente
Instituto Universitario de Investigación en Tecnología Centrada en el Ser Humano, Universitat Politècnica de València, Valencia, Spain
Geert Litjens
Geert Litjens
Radboud University Medical Center
digital pathologycomputer-aided detectionMRIprostate cancerbreast cancer
S
Salma Dammak
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands; On behalf of the Bigpicture Consortium